Department of Urology, University of Verona, Azienda Ospedaliera Universitaria Integrata Verona, Piazzale Stefani 1, 37126, Verona, Italy.
Institute of Urology and Catherine and Joseph Aresty Department of Urology, University of Southern California (USC), Los Angeles, USA.
World J Urol. 2020 Nov;38(11):2799-2809. doi: 10.1007/s00345-020-03094-2. Epub 2020 Jan 24.
To evaluate the factors associated with the risk of hospital readmission after robot assisted radical prostatectomy (RARP) with or without extended pelvic lymph node dissection (ePLND) for prostate cancer (PCA) over a long term.
The risk of readmission was evaluated by clinical, pathological, and perioperative factors. Skilled and experienced surgeons performed the procedures. Patients were followed for complications and hospital readmission for a period of six months. The logistic regression model and Cox's proportional hazards assessed the association of factors with the risk of readmission.
From January 2013 to December 2018, 890 patients underwent RARP; ePLND was performed in 495 of these patients. Hospital readmission was detected in 25 cases (2.8%); moreover, it was more frequent when RARP was performed with ePLND (4.4% of cases) than without (0.8% of patients). On the final multivariate model, ePLND was the only independent factor that was positively associated with the risk of hospital readmission (hazard ratio, HR = 5935; 95%CI 1777-19,831; p = 0.004).
Over the long term after RARP for PCA, the risk of hospital readmission is associated with ePLND. In patients who underwent RARP and ePLND, 4.4% of them had a readmission, compared to RARP alone, in which only 0.8% of cases had a readmission. When ePLND is planned for staging pelvic lymph nodes, patients should be informed of the increased risk of hospital readmission.
评估机器人辅助根治性前列腺切除术(RARP)治疗前列腺癌(PCA)后长期住院再入院风险的相关因素,包括是否行扩大盆腔淋巴结清扫术(ePLND)。
通过临床、病理和围手术期因素评估再入院风险。熟练且经验丰富的外科医生实施手术。患者随访 6 个月以观察并发症和再入院情况。使用逻辑回归模型和 Cox 比例风险评估各因素与再入院风险的关系。
2013 年 1 月至 2018 年 12 月,890 例患者接受了 RARP 治疗,其中 495 例患者行 ePLND。25 例(2.8%)患者发生再入院,RARP 联合 ePLND 组(4.4%)再入院率高于 RARP 组(0.8%)。多因素模型分析显示,ePLND 是唯一与再入院风险相关的独立因素(风险比 HR=5935;95%可信区间 1777-19831;p=0.004)。
PCA 患者行 RARP 治疗后长期再入院风险与 ePLND 相关。RARP 联合 ePLND 组 4.4%的患者再入院,而单纯 RARP 组仅 0.8%的患者再入院。对行淋巴结分期的患者计划行 ePLND 时,应告知其再入院风险增加。